GC Biotherapeutics Inc.

GC Biotherapeutics Inc. (GCBT) is the strategic foothold for GC’s business expansion to the North American and European markets. We are building a state of the art bio-manufacturing facility for plasma proteins and will be the only Intravenous Immunoglobulin (IVIG) and Albumin producer in Canada.

More

Product list

GC Biotherapeutics Inc. (GCBT) will initially manufacture two products: Intravenous Immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and Albumin, used as a blood-volumizing agent.                                                                                     

More

Contact us

For all inquiries about GC Biotherapeutics Inc., Project Oasis, corporate information, customer relations or about any of our products, click “More” to send us a message.

More

Recent News

15Apr

GC Pharma Marks ‘World Hemophilia Day’

0 Comments
YONGIN, South Korea, April 15, 2019 /CNW/ — GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, joins World... Read More →
03Apr

Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug

0 Comments
YONGIN, South Korea, April 3, 2019 /CNW/ — Clinigen K.K. and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today... Read More →

A Major Project in Canada

Project Oasis

Project Oasis is a plan to expand GC’s business to North America and Europe. Its Montreal plant will be the project’s focal point. $400 million will be invested in Canada’s only intravenous immunoglobulin (IVIG) and albumin manufacturing plant and in sourcing essential raw materials. We are honoured to receive strategic support from Investissement Quebec and that the Korean National Pension Services has invested in us.

More

This post is also available in: frFrançais (French)

Back to Top